EGEva Gijbels

Eva Gijbels

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eva Gijbels has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Methodology and quality assurance practices in performing anti-extractable nuclear antigen (ENA) analysis: an EFLM report on an international survey

    by Eva Gijbels, Stijn De Koninck, Sylvia Broeders, Edward K.L. Chan, Nicola Bizzaro, Dimitrios P. Bogdanos, Luis Andrade, Wim Coucke, Wilson de Melo Cruvinel, Ana Kozmar, et al.

    Objectives: Autoantibodies to extractable nuclear antigens (anti-ENA) play a crucial role in the diagnosis of systemic autoimmune rheumatic diseases (SARD). Analytical methods differ in antigen composition and diagnostic performance. We aimed to document the extent of variability amongst laboratories in how anti-ENA testing is conducted, controlled and verified. Methods: A survey was developed to collect information on anti-ENA methodology and quality assurance practices. The questionnaire was distributed amongst laboratories by Sciensano (Belgium), national EASI groups (Italy, Croatia, Portugal, Estonia, Greece) and ICAP (worldwide). Results: A total of 427 laboratories participated (61 % European, 21 % American, 14 % Asian). More than half (52 %) use two or more anti-ENA methods. Turnaround time varied, but 71 % perform the analysis within 72 h. Urgent testing was offered in 42 % of laboratories. Internal quality control (IQC) was performed in 91 % of laboratories, predominantly with commercial materials. External quality assessment (EQA) participation was also high (87 %), with nearly half participating in more than three distributions annually. Reagent lot evaluation was less widely implemented (36 %). Forty-three percent tried to limit variability by limiting lot changes. Method verification was performed by 81 % of the laboratories, though sample type and numbers, as well as reproducibility replicates varied considerably. Conclusions: This survey highlights substantial heterogeneity in anti-ENA laboratory practice. While most laboratories apply IQC and EQA, significant variation remains in test method(s), turnaround times, lot variability evaluation and verification strategies. Development of more comprehensive recommendations on these topics are essential to improve reliability and comparability of results across laboratories.

  • Open Access

    Osteopontin characterizes bile duct–associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis

    by Kevin De Muynck, Lander Heyerick, Federico F. De Ponti, Bart Vanderborght, Tim Meese, Sanne Van Campenhout, Leen Baudonck, Eva Gijbels, Pedro M. Rodrigues, Jesus M. Banales, et al.

    Background and Aims: Primary sclerosing cholangitis (PSC) is an immune-mediated cholestatic liver disease for which pharmacological treatment options are currently unavailable. PSC is strongly associated with colitis and a disruption of the gut-liver axis, and macrophages are involved in the pathogenesis of PSC. However, how gut-liver interactions and specific macrophage populations contribute to PSC is incompletely understood. Approach and Results: We investigated the impact of cholestasis and colitis on the hepatic and colonic microenvironment, and performed an in-depth characterization of hepatic macrophage dynamics and function in models of concomitant cholangitis and colitis. Cholestasis-induced fibrosis was characterized by depletion of resident KCs, and enrichment of monocytes and monocyte-derived macrophages (MoMFs) in the liver. These MoMFs highly express triggering-receptor-expressed-on-myeloid-cells-2 (Trem2) and osteopontin (Spp1), markers assigned to hepatic bile duct-associated macrophages, and were enriched around the portal triad, which was confirmed in human PSC. Colitis induced monocyte/macrophage infiltration in the gut and liver, and enhanced cholestasis-induced MoMF-Trem2 and Spp1 upregulation, yet did not exacerbate liver fibrosis. Bone marrow chimeras showed that knockout of Spp1 in infiltrated MoMFs exacerbates inflammation in vivo and in vitro, while monoclonal antibody–mediated neutralization of SPP1 conferred protection in experimental PSC. In human PSC patients, serum osteopontin levels are elevated compared to control, and significantly increased in advanced stage PSC and might serve as a prognostic biomarker for liver transplant-free survival. Conclusions: Our data shed light on gut-liver axis perturbations and macrophage dynamics and function in PSC and highlight SPP1/OPN as a prognostic marker and future therapeutic target in PSC.


  • Kupffer Cells Contested as Early Drivers in the Pathogenesis of Primary Sclerosing Cholangitis

    by Kevin De Muynck, Bart Vanderborght, Federico F. De Ponti, Eva Gijbels, Sophie Van Welden, Martin Guilliams, Charlotte L. Scott, Alain Beschin, Mathieu Vinken, Sander Lefere, et al.


  • Open Access

    Expression of connexins and pannexins in diseased human liver

    by Kaat Leroy, Vânia Vilas-Boas, Eva Gijbels, Bart Vanderborght, Lindsey Devisscher, Bruno Cogliati, Bert Van Den Bossche, Isabelle Colle, Mathieu Vinken

    Connexin proteins can form hexameric hemichannels and gap junctions that mediate paracrine and direct intercellular communication, respectively. Gap junction activity is crucial for the maintenance of hepatic homeostasis, while connexin hemichannels become particularly active in liver disease, such as hepatitis, fibrosis, cholestasis or even hepatocellular carcinoma. Channels consisting of connexin-like proteins named pannexins have been directly linked to liver inflammation and cell death. The goal of the present study was to characterize the expression and subcellular localization of connexins and pannexins in liver of patients suffering from various chronic and neoplastic liver diseases. Specifically, real-time quantitative reverse transcription polymerase chain reaction, immunoblotting and immunohistochemistry analyses were performed on human liver biopsies. It was found that pannexin1 and pannexin2 gene expression are correlated to a certain degree, as is pannexin1 protein expression with connexin32 and connexin43 protein expression. Furthermore, this study is the first to detect pannexin3 in human patient liver biopsies via both immunoblot and immunohistochemistry.


  • Open Access

    Systematic comparison of experimental and human obstructive cholestasis reveals conservation of canonical pathway activation and biomarkers relevant for cholestatic liver disease

    by Eva Gijbels, Kevin De Muynck, Bart Vanderborght, Tim Meese, Filip Van Nieuwerburgh, Aude Vanlander, Frederik Berrevoet, Bart Hendrikx, Anne Hoorens, Hans Van Vlierberghe, et al.


  • Open Access

    Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals

    by Vânia Vilas-Boas, Eva Gijbels, Kaat Leroy, Alanah Pieters, Audrey Baze, Céline Parmentier, Mathieu Vinken

    Drug-induced liver injury, including cholestasis, is an important clinical issue and economic burden for pharmaceutical industry and healthcare systems. However, human-relevant in vitro information on the ability of other types of chemicals to induce cholestatic hepatotoxicity is lacking. This work aimed at investigating the cholestatic potential of non-pharmaceutical chemicals using primary human hepatocytes cultured in 3D spheroids. Spheroid cultures were repeatedly (co-) exposed to drugs (cyclosporine-A, bosentan, macitentan) or non-pharmaceutical chemicals (paraquat, tartrazine, triclosan) and a concentrated mixture of bile acids for 4 weeks. Cell viability (adenosine triphosphate content) was checked every week and used to calculate the cholestatic index, an indicator of cholestatic liability. Microarray analysis was performed at specific time-points to verify the deregulation of genes related to cholestasis, steatosis and fibrosis. Despite the evident inter-donor variability, shorter exposures to cyclosporine-A consistently produced cholestatic index values below 0.80 with transcriptomic data partially supporting its cholestatic burden. Bosentan confirmed to be hepatotoxic, while macitentan was not toxic in the tested concentrations. Prolonged exposure to paraquat suggested fibrotic potential, while triclosan markedly deregulated genes involved in different types of hepatotoxicity. These results support the applicability of primary human hepatocyte spheroids to study hepatotoxicity of non-pharmaceutical chemicals in vitro.


  • Open Access

    In Vitro Liver Toxicity Testing of Chemicals: A Pragmatic Approach

    by Andrés Tabernilla, Bruna dos Santos Rodrigues, Alanah Pieters, Anne Caufriez, Kaat Leroy, Raf Van Campenhout, Axelle Cooreman, Ana Rita Gomes, Emma Arnesdotter, Eva Gijbels, et al.

    The liver is among the most frequently targeted organs by noxious chemicals of diverse nature. Liver toxicity testing using laboratory animals not only raises serious ethical questions, but is also rather poorly predictive of human safety towards chemicals. Increasing attention is, therefore, being paid to the development of non-animal and human-based testing schemes, which rely to a great extent on in vitro methodology. The present paper proposes a rationalized tiered in vitro testing strategy to detect liver toxicity triggered by chemicals, in which the first tier is focused on assessing general cytotoxicity, while the second tier is aimed at identifying liver-specific toxicity as such. A state-of-the-art overview is provided of the most commonly used in vitro assays that can be used in both tiers. Advantages and disadvantages of each assay as well as overall practical considerations are discussed.


  • Biomarkers of Cholestasis

    by Alanah Pieters, Eva Gijbels, Bruno Cogliati, Pieter Annaert, Lindsey Devisscher, Mathieu Vinken

    Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The freq...